-
Definium Therapeutics updates DT120 clinical trials and commercial plans
-
Psychedelic stocks soar after Trump signs executive order to fast-track treatments
-
Stifel Starts Definium Therapeutics Inc (DFTX) at Buy
-
White House Prepares Order On Ibogaine Psychedelic - CBS
-
Piper Sandler Starts Definium Therapeutics Inc (DFTX) at Overweight
-
Definium study shows anxiety disorder prevalence rose to 6.6% in 2023
-
Wolfe Research Starts Definium Therapeutics Inc (DFTX) at Outperform, Top Pick
-
Definium Therapeutics (DFTX) Reiterated at Overweight by Cantor Fitzgerald
-
Jefferies Starts Definium Therapeutics Inc (DFTX) at Buy
-
Definium Therapeutics Inc (DFTX) PT Raised to $36 at RBC Capital
-
Definium Therapeutics launches educational campaign on LSD research
-
Definium Therapeutics delays ticker change to DFTX until January 15

